Triple Therapy vs. Dual Bronchodilators: Impact on Air Trapping and Inflammation in COPD

This study focuses on people with Chronic Obstructive Pulmonary Disease, commonly known as COPD, which affects breathing. It aims to compare the effects of two different treatments: one involves a combination of three medications, Fluticasone Furoate, Vilanterol, and Umeclidinium (triple therapy), and the other uses just two, Vilanterol and Umeclidinium (dual bronchodilators). The goal is to see how these treatments help with reducing air getting trapped in the lungs and also how they affect substances in the body that are linked to inflammation. This is important because managing air trapping and inflammation can significantly improve breathing and quality of life for those with COPD. Participants in the study will receive the treatments, which are typically administered through inhalation. The study will observe how well each treatment works by measuring the amount of air trapped in the lungs and examining levels of inflammatory substances in both the airways and blood. By comparing these results, researchers hope to identify which treatment is more effective in managing symptoms of COPD. The study is in Phase 3, which means it is focused on confirming the effectiveness of these treatments in a larger group of people. There are no specific risks or benefits mentioned, but generally, such studies aim to establish treatments that are both effective and safe.